Mayo Clinic has partnered with nference to form a new startup company, Qrativ, that will implement artificial intelligence (AI) to aid in the discovery of new medicines. Mayo Clinic will utilize nferX – an AI platform from nference – to quickly data mine large volumes of medical literature and clinical data in order to collect insights into disease. Those insights will be used to guide the development of new drugs, with earlier phases being focused on rare diseases and highly targeted patient populations.
Qrativ continues the current market trend of health organizations investing heavily into AI for research and treatment purposes. It is anticipated that the large amount of information the AI platform can sift through will allow researchers to obtain insights on clinical data that would not be possible through human research.
The Mayo Clinic is a nonprofit medical practice and medical research group. Nference is an American tech company that uses Neural Networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific, and regulatory body of literature.
This was reported by Pharmaphorum on July 19, 2017.
Contact Information: Mayo Clinic Headquarters, 200 First Street Southwest, Rochester, Minnesota 55905; (507) 284-2511; Website: www.mayoclinic.org
Contact Information: Nference, 101 Main Street 14th Floor, Cambridge, Massachusetts 02142; Email: email@example.com; Website: www.nference.ai